Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer

CancerCare Manitoba

Status and phase: Terminated; Phase 2

Conditions: Non-small Cell Lung Cancer

Treatments: Drug: finasteride 5mg oral daily

Study type: Interventional

Funder types: Other

Identifiers

NCT02055170

HLC001

Details and patient eligibility

About

The purpose of this study is to study the effect of hormone therapies (androgen pathway modification) on the outcomes of patients with lung cancer. This information may be of benefit for future treatment strategies, prevention and control.

In this study, the protein where testosterone binds, called the androgen receptor (AR), will be measured in samples from the patient's biopsy and surgical tumor samples. The investigators will look at a marker of how fast the cancer is growing (Ki67) before using finasteride from your biopsy specimen. Finasteride will be taken from the day of consent until the day of the patient's surgery. This marker will be measured again after using finasteride from the surgical specimen. The investigators will be looking for a decrease in the Ki67 from the patient's biopsy specimen to the surgical specimen as an indicator that this medication is blocking tumour growth.

Enrollment: 4 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• male
• age >18
• biopsy-proven non-small cell lung cancer
• surgical intervention planned

Exclusion criteria

• current use of 5-alpha reductase inhibitor
• previous diagnosis of prostate cancer
• previous hypersensitivity to 5-alpha reductase inhibitor

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

4 participants in 1 patient group

finasteride

Experimental group

Description:

finasteride 5mg po od from study entry to date of surgery

Treatment:

Drug: finasteride 5mg oral daily